Roche Submits sNDA For New Chemotherapy Regimen In Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Application is for Xelox (Xeloda plus oxaliplatin) with or without Genentech’s Avastin.
You may also be interested in...
The angiogenesis inhibitor gets full FDA approval Feb. 26. Genentech said it will begin shipping the biologic within three days.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.